Celltrion to Initiate P-I trial for CT-P39 (biosimilar- omalizumab)

Share this
Celltrion to Initiate P-I trial for CT-P39 (biosimilar- omalizumab)

Celltrion to Initiate P-I trial for CT-P39 (biosimilar- omalizumab)


  • Celltrion plans for the onset of P-I trial for CT-P39 referencing Xolair- and further plans to enter P-III trial in H1’20 with its expected commercialization by 2020
  • The P-I trial will involve assessing of CT-P39-EU-licensed Xolair and US-licensed Xolair evaluating PK and safety in 171 patients in with its expected completion in Aug’20. In Dec 2018- Celltrion began to develop CT-P39 and is focused on the US markets accounting for ~70% of the branded drug’s global sales
  • CT-P39 is a mAb targeted for the treatment of allergic asthma and chronic urticaria. According- to IQVIA- the global sales Xolair reached 3.3 trillion won ($2.7 billion) in 2018

Click here to read full press release/ article | Ref: Celltrion | Image: Celltrion


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions